Natalizumab discontinuation: an increasingly tricky proposition

Eur J Neurol. 2012 May;19(5):663-4. doi: 10.1111/j.1468-1331.2011.03574.x. Epub 2011 Nov 7.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Female
  • Humans
  • Immunologic Factors / therapeutic use*
  • Male
  • Multiple Sclerosis / drug therapy*
  • Natalizumab
  • Product Surveillance, Postmarketing*

Substances

  • Antibodies, Monoclonal, Humanized
  • Immunologic Factors
  • Natalizumab